drugset / Trial / NCT06671548
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
RandomizedParallel-groupTriple-blindTreatment
Summary
The goal of this clinical trial is to determine the benefit of relugolix 40 milligrams (mg) once a day compared with placebo in heavy menstrual bleeding associated with uterine fibroids. The main question\[s\] it aims to answer are: * the benefit of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids * the safety of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids
Timeline
- Start
- 2024-01-15
- Primary completion
- 2026-11-12
- Completion
- 2027-01-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relugolix | Small molecule | 40 mg | Oral |
| Background | Megestrol Acetate | Other / unclassified | 1 mg | Oral |
| Background | medroxyprogesterone acetate | Other / unclassified | 2 mg | Oral |